Literature DB >> 20363480

Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction.

J Raymond Fitzpatrick1, John R Frederick, Ryan C McCormick, David A Harris, Ah-Young Kim, Jeffrey R Muenzer, Alex J Gambogi, Jing Ping Liu, E Carter Paulson, Y Joseph Woo.   

Abstract

OBJECTIVE: Microvascular malperfusion after myocardial infarction leads to infarct expansion, adverse remodeling, and functional impairment. Native reparative mechanisms exist but are inadequate to vascularize ischemic myocardium. We hypothesized that a 3-dimensional human fibroblast culture (3DFC) functions as a sustained source of angiogenic cytokines, thereby augmenting native angiogenesis and limiting adverse effects of myocardial ischemia.
METHODS: Lewis rats underwent ligation of the left anterior descending coronary artery to induce heart failure; experimental animals received a 3DFC scaffold to the ischemic region. Border-zone tissue was analyzed for the presence of human fibroblast surface protein, vascular endothelial growth factor, and hepatocyte growth factor. Cardiac function was assessed with echocardiography and pressure-volume conductance. Hearts underwent immunohistochemical analysis of angiogenesis by co-localization of platelet endothelial cell adhesion molecule and alpha smooth muscle actin and by digital analysis of ventricular geometry. Microvascular angiography was performed with fluorescein-labeled lectin to assess perfusion.
RESULTS: Immunoblotting confirmed the presence of human fibroblast surface protein in rats receiving 3DFC, indicating survival of transplanted cells. Increased expression of vascular endothelial growth factor and hepatocyte growth factor in experimental rats confirmed elution by the 3DFC. Microvasculature expressing platelet endothelial cell adhesion molecule/alpha smooth muscle actin was increased in infarct and border-zone regions of rats receiving 3DFC. Microvascular perfusion was also improved in infarct and border-zone regions in these rats. Rats receiving 3DFC had increased wall thickness, smaller infarct area, and smaller infarct fraction. Echocardiography and pressure-volume measurements showed that cardiac function was preserved in these rats.
CONCLUSIONS: Application of a bioengineered 3DFC augments native angiogenesis through delivery of angiogenic cytokines to ischemic myocardium. This yields improved microvascular perfusion, limits infarct progression and adverse remodeling, and improves ventricular function. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20363480      PMCID: PMC4175745          DOI: 10.1016/j.jtcvs.2009.12.037

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  35 in total

1.  Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.

Authors:  T D Henry; K Rocha-Singh; J M Isner; D J Kereiakes; F J Giordano; M Simons; D W Losordo; R C Hendel; R O Bonow; S M Eppler; T F Zioncheck; E B Holmgren; E R McCluskey
Journal:  Am Heart J       Date:  2001-11       Impact factor: 4.749

2.  Correlation of autologous skeletal myoblast survival with changes in left ventricular remodeling in dilated ischemic heart failure.

Authors:  Patrick I McConnell; Carlos L del Rio; Douglas B Jacoby; Martina Pavlicova; Pawel Kwiatkowski; Agatha Zawadzka; Jonathan H Dinsmore; Louis Astra; Sheik Wisel; Robert E Michler
Journal:  J Thorac Cardiovasc Surg       Date:  2005-09-02       Impact factor: 5.209

3.  Echocardiographic assessment of cardiac structure and function in rats.

Authors:  Lindsay Brown; Andrew Fenning; Vincent Chan; David Loch; Kathleen Wilson; Bonita Anderson; Darryl Burstow
Journal:  Heart Lung Circ       Date:  2002       Impact factor: 2.975

4.  Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure.

Authors:  Vasant Jayasankar; Y Joseph Woo; Timothy J Pirolli; Lawrence T Bish; Mark F Berry; Jeffrey Burdick; Timothy J Gardner; H Lee Sweeney
Journal:  J Card Surg       Date:  2005 Jan-Feb       Impact factor: 1.620

5.  Scaffold-based three-dimensional human fibroblast culture provides a structural matrix that supports angiogenesis in infarcted heart tissue.

Authors:  R S Kellar; L K Landeen; B R Shepherd; G K Naughton; A Ratcliffe; S K Williams
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

6.  Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up.

Authors:  Juan J Gavira; Jesús Herreros; Ana Perez; María José Garcia-Velloso; Joaquín Barba; Francisco Martin-Herrero; Consuelo Cañizo; Ana Martin-Arnau; Josep M Martí-Climent; Milagros Hernández; Natalia López-Holgado; José María González-Santos; Cándido Martín-Luengo; Eduardo Alegria; Felipe Prósper
Journal:  J Thorac Cardiovasc Surg       Date:  2006-04       Impact factor: 5.209

7.  Improvement of contractility accompanies angiogenesis rather than arteriogenesis in chronic myocardial ischemia.

Authors:  Claudia Heilmann; Caterina Kostic; Bodo Giannone; Andrea Busse Grawitz; Werner Armbruster; Georg Lutter; Friedhelm Beyersdorf; Heike Göbel
Journal:  Vascul Pharmacol       Date:  2006-03-09       Impact factor: 5.773

8.  Locally overexpressing hepatocyte growth factor prevents post-ischemic heart failure by inhibition of apoptosis via calcineurin-mediated pathway and angiogenesis.

Authors:  Yinghua Guo; Jianguo He; Junlou Wu; Long Yang; Shimo Dai; Xiaoyan Tan; Lirong Liang
Journal:  Arch Med Res       Date:  2008-02       Impact factor: 2.235

9.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts.

Authors:  Michael A Laflamme; Kent Y Chen; Anna V Naumova; Veronica Muskheli; James A Fugate; Sarah K Dupras; Hans Reinecke; Chunhui Xu; Mohammad Hassanipour; Shailaja Police; Chris O'Sullivan; Lila Collins; Yinhong Chen; Elina Minami; Edward A Gill; Shuichi Ueno; Chun Yuan; Joseph Gold; Charles E Murry
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

Review 10.  Pro-angiogenic cytokines as cardiovascular therapeutics: assessing the potential.

Authors:  Pavan Atluri; Y Joseph Woo
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

View more
  9 in total

1.  Myocardial tissue elastic properties determined by atomic force microscopy after stromal cell-derived factor 1α angiogenic therapy for acute myocardial infarction in a murine model.

Authors:  William Hiesinger; Matthew J Brukman; Ryan C McCormick; J Raymond Fitzpatrick; John R Frederick; Elaine C Yang; Jeffrey R Muenzer; Nicole A Marotta; Mark F Berry; Pavan Atluri; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2012-01-20       Impact factor: 5.209

2.  An electrically coupled tissue-engineered cardiomyocyte scaffold improves cardiac function in rats with chronic heart failure.

Authors:  Jordan J Lancaster; Elizabeth Juneman; Sarah A Arnce; Nicholle M Johnson; Yexian Qin; Russell Witte; Hoang Thai; Robert S Kellar; Jose Ek Vitorin; Janis Burt; Mohamed A Gaballa; Joseph J Bahl; Steven Goldman
Journal:  J Heart Lung Transplant       Date:  2013-12-17       Impact factor: 10.247

3.  Myocardial regenerative therapy using a scaffold-free skeletal-muscle-derived cell sheet in patients with dilated cardiomyopathy even under a left ventricular assist device: a safety and feasibility study.

Authors:  Yasushi Yoshikawa; Shigeru Miyagawa; Koichi Toda; Atsuhiro Saito; Yasushi Sakata; Yoshiki Sawa
Journal:  Surg Today       Date:  2017-08-18       Impact factor: 2.549

4.  Nanoparticles targeting the infarcted heart.

Authors:  Tal Dvir; Michael Bauer; Avi Schroeder; Jonathan H Tsui; Daniel G Anderson; Robert Langer; Ronglih Liao; Daniel S Kohane
Journal:  Nano Lett       Date:  2011-09-14       Impact factor: 11.189

Review 5.  Therapeutic application of nanotechnology in cardiovascular and pulmonary regeneration.

Authors:  Young Wook Chun; Spencer W Crowder; Steven C Mehl; Xintong Wang; Hojae Bae; Hak-Joon Sung
Journal:  Comput Struct Biotechnol J       Date:  2013-09-21       Impact factor: 7.271

6.  Photobiomodulation plus Adipose-derived Stem Cells Improve Healing of Ischemic Infected Wounds in Type 2 Diabetic Rats.

Authors:  Ali Moradi; Fatemeh Zare; Atarodsadat Mostafavinia; Sobhan Safaju; Amirhossein Shahbazi; Malihe Habibi; Mohammad-Amin Abdollahifar; Seyed Mahmoud Hashemi; Abdollah Amini; Seyed Kamran Ghoreishi; Sufan Chien; Michael R Hamblin; Reza Kouhkheil; Mohammad Bayat
Journal:  Sci Rep       Date:  2020-01-27       Impact factor: 4.379

7.  Dermagraft: Use in the Treatment of Chronic Wounds.

Authors:  Charles E Hart; Andrea Loewen-Rodriguez; Jan Lessem
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-06       Impact factor: 4.730

8.  Calcium-alginate hydrogel-encapsulated fibroblasts provide sustained release of vascular endothelial growth factor.

Authors:  Nicola C Hunt; Richard M Shelton; Deborah J Henderson; Liam M Grover
Journal:  Tissue Eng Part A       Date:  2012-12-07       Impact factor: 3.845

9.  CD73+ extracellular vesicles inhibit angiogenesis through adenosine A2B receptor signalling.

Authors:  Roberta Angioni; Cristina Liboni; Stephanie Herkenne; Ricardo Sánchez-Rodríguez; Giulia Borile; Elisabetta Marcuzzi; Bianca Calì; Maurizio Muraca; Antonella Viola
Journal:  J Extracell Vesicles       Date:  2020-05-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.